TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9153693

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Amitriptyline with standard clinical management
Number of subjects: 91

Group type: COMPARATOR
Intervention: Drug placebo with standard clinical management
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 91
Study: 8484513

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air
Number of subjects: 40
Study: 2974302

Group type: EXPERIMENTAL
Intervention: PTFE (Gore‐Tex CV patch)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Autogenous saphenous vein
Number of subjects: 71

Group type: COMPARATOR
Intervention: Dacron velour (Sauvage Filamentous)
Number of subjects: 71
Study: 29503083

Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 502

Group type: COMPARATOR
Intervention: Meta-analysis of three trials (IMPROVE, AJAX, ECAR)
Number of subjects: 502
Study: 25757867

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Early decrease of 24h proteinuria <0.5g/day at 3, 6, and 12 months
Number of subjects: 105
Study: 24102655

Group type: EXPERIMENTAL
Intervention: Internal peer-review training for nurses
Number of subjects: 0
Study: 21258804

Group type: EXPERIMENTAL
Intervention: Mud pack therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hot pack therapy
Number of subjects: 44
Study: 20102667

Group type: EXPERIMENTAL
Intervention: Propranolol (β-noradrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual control regions
Number of subjects: 0
Study: 18825580

Group type: EXPERIMENTAL
Intervention: CPAG (Physical Activity Guide to Healthy Active Living)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 130
Study: 16377919

Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF) 0.15-0.3 mg/kg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lidocaine (LID)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF)
Number of subjects: 91
Study: 12822874

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b + Ribavirin (1000-1200 mg/day for 48 weeks)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Interferon-alpha2b + Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b + Ribavirin
Number of subjects: 125
Study: 11402829

Group type: EXPERIMENTAL
Intervention: Viscoelastics (ophthalmic viscosurgical device, OVD)
Number of subjects: 11
Study: 9414366

Group type: EXPERIMENTAL
Intervention: Laptop computer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desktop computer
Number of subjects: 0
Study: 8428323

Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2 orally daily for up to 2 years
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: estramustine phosphate adjuvant
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: adjuvant estramustine phosphate
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: adjuvant cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Number of subjects: 437

Group type: COMPARATOR
Intervention: no adjuvant therapy
Number of subjects: 437
Study: 2892864

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 10 PM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 20
Study: 28003041

Group type: EXPERIMENTAL
Intervention: Oat consumption group (50 g/day oats)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (recommended to reduce intake of dietary protein, phosphorus, sodium and potassium)
Number of subjects: 52
Study: 28719294

Group type: EXPERIMENTAL
Intervention: Skeleton-binding protein 1 (SBP1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REX1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHISTb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Established markers (18S DNA and rRNA, Pfs25 mRNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo clinical trial samples
Number of subjects: 0
Study: 26181703

Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 336
Study: 24012319

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg tablets twice daily
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 258
Study: 21128152

Group type: EXPERIMENTAL
Intervention: Culturally derived metaphor (i.e., sex of a baby)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Standard metaphor (i.e., flip of a coin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low-literacy definition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Attention (moderator)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Positive affective response to the randomization message
Number of subjects: 64
Study: 19061374

Group type: EXPERIMENTAL
Intervention: L-Dopa (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17333809

Group type: EXPERIMENTAL
Intervention: Doxycycline, 2 x 200 mg/day for 1 week
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel, single dose, 40 mg/kg body weight
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxytetracycline, 15 mg in 0.5 mL medium (in vitro)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extract of Myrtus communis (in vitro)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extract of Eucalyptus comaldensis, 50 mg in 0.1 mL medium (in vitro)
Number of subjects: 6
Study: 14727945

Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 10724022

Group type: EXPERIMENTAL
Intervention: pivmecillinam, 200 mg three times daily for 3 days
Number of subjects: 216

Group type: COMPARATOR
Intervention: cephalexin, 250 mg four times daily for 7 days
Number of subjects: 216
Study: 8730167

Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against 10% sodium lauryl sulfate (SLS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against undiluted toluene (TOL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against 1% sodium hydroxide (NaOH) and 30% lactic acid (LA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against SLS and NaOH
Number of subjects: 20
Study: 29568693

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study: 28764800

Group type: EXPERIMENTAL
Intervention: Participation in the neonatal trial
Number of subjects: 0
Study: 26596013

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection as initial treatment (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Systemic hormone therapy (group B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection as salvage treatment (group C)
Number of subjects: 63
Study: 24198750

Group type: EXPERIMENTAL
Intervention: Information leaflet supplemented with numerical data on cancer risk and effects of HPV vaccination
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard leaflet on HPV vaccination
Number of subjects: 105
Study: 20617919

Group type: EXPERIMENTAL
Intervention: Paraffin baths 80% wax with 20% topical analgesic (PTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin baths only (PO) (100% wax)
Number of subjects: 0
Study: 18302501

Group type: EXPERIMENTAL
Intervention: 10 min of jumping activity in place of regular physical education (PE) warm up
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual PE warm-up activities
Number of subjects: 99
Study: 16292564

Group type: EXPERIMENTAL
Intervention: Prophylactic surgery (total colectomy or restorative proctocolectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic intervention for endometrium and stomach
Number of subjects: 0
Study: 12462285

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 482

Group type: COMPARATOR
Intervention: All active treatments
Number of subjects: 482
Study: 10336539

Group type: EXPERIMENTAL
Intervention: Morphine (MOR) 2.5, 5, and 10 mg/70 kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM) 0.33, 0.65, and 1.3 mg/70 kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meperidine (MEP) 17.5, 35, and 70 mg/70 kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (SAL)
Number of subjects: 16
Study: 8571416

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071
Study: 2021128

Group type: EXPERIMENTAL
Intervention: Fatty Fish (FF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Red Meat (RM)
Number of subjects: 28
Study: 7172618

Group type: EXPERIMENTAL
Intervention: Clients who chose their own therapist after viewing a slide/sound presentation.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clients assigned to a therapist by the clinical director after viewing the presentation.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clients assigned to a therapist by the clinical director without viewing the presentation.
Number of subjects: 42
Study: 30058511

Group type: EXPERIMENTAL
Intervention: Discontinued antipsychotic treatment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Continued antipsychotic treatment
Number of subjects: 189
Study: 28720617

Group type: EXPERIMENTAL
Intervention: Relatives Education And Coping Toolkit (REACT)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Resource Directory (RD) only
Number of subjects: 666
Study: 27531506

Group type: EXPERIMENTAL
Intervention: Intensified, multifactorial treatment (mean treatment duration 7.8 years)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intensified, multifactorial treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 160
Study: 24418924

Group type: EXPERIMENTAL
Intervention: 2D video preparation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3D video preparation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Guide preparation
Number of subjects: 84
Study: 22616081

Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 60
Study: 19387389

Group type: EXPERIMENTAL
Intervention: Nonmotorized treadmill exercise at varying speeds (3.22, 4.83, 6.44, 8.05, 9.66, and 11.27 km/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonmotorized treadmill exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Graded exercise test on a standard treadmill
Number of subjects: 20
Study: 17365741

Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Plain cigarettes
Number of subjects: 5887
Study: 15535489

Group type: EXPERIMENTAL
Intervention: ephedrine 30 microg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: lignocaine 2% (40 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 93
Study: 11674912

Group type: EXPERIMENTAL
Intervention: 50% dextrose solution
Number of subjects: 71

Group type: COMPARATOR
Intervention: Water
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 71
Study: 9477007

Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone 12 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone 16 mg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone (>= 4 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone 1 or 4 mg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Risperidone (optimal dose)
Number of subjects: 141
Study: 8200988

Group type: EXPERIMENTAL
Intervention: IgA anti-CD3 mAb (T3.A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IgG2a anti-CD3 mAb (T3.G2a)
Number of subjects: 20
Study: 3363287

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg/day for 3 days
Number of subjects: 6
Study: 30419120

Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 days, twice daily)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Placebo (3 days, twice daily)
Number of subjects: 1126
Study: 27848159

Group type: EXPERIMENTAL
Intervention: Recent chemotherapy (Group R)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No recent chemotherapy (Group O)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 120
Study: 25172089

Group type: EXPERIMENTAL
Intervention: 12-month home-based exercise programme
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 23760292

Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-sodium/low-potassium diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet with furosemide infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ad libitum sodium/potassium diet
Number of subjects: 40
Study: 21226788

Group type: EXPERIMENTAL
Intervention: Theory of planned behaviour (TPB) cognitions
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Objective energy expenditure measurement
Number of subjects: 365
Study: 18164013

Group type: EXPERIMENTAL
Intervention: CETP lowering B2 allele and HL lowering LIPC-T allele
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: B1B1/CC genotype
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: B2B2/TT genotype
Number of subjects: 792

Group type: COMPARATOR
Intervention: Coronary artery lumen diameter loss
Number of subjects: 792
Study: 17062300

Group type: EXPERIMENTAL
Intervention: Paracetamol tablet containing sodium bicarbonate (PSC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 12702521

Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Epirubicin-Cyclophosphamide at intermediate doses (EC)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Epirubicin-Cyclophosphamide at full doses (HEC)
Number of subjects: 777
Study: 10547215

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg q.i.d.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8722731

Group type: EXPERIMENTAL
Intervention: Total BDI scores
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Body image distortion
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Loss of appetite
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Crying
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Pessimism
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Failure
Number of subjects: 245
Study: 1687238

Group type: EXPERIMENTAL
Intervention: Mequitazine (MQZ) 5 mg BID for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (saline or histamine prick test)
Number of subjects: 29
Study: 6364621

Group type: EXPERIMENTAL
Intervention: 25 mg phenylethylamine in apple juice
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Four different wines (2 dl) containing biogenic amines
Number of subjects: 47

Group type: COMPARATOR
Intervention: 25 mg histamine in apple juice
Number of subjects: 47

Group type: COMPARATOR
Intervention: 25 mg tyramine in apple juice
Number of subjects: 47
Study: 30251255

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 40
Study: 31748594

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg tablet) administered once daily for 2 months (Mo2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg tablet) administered once daily for 4 months (Mo4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study: 27913736

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (1g in 100mL normal saline during sternal closure)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid
Number of subjects: 82
Study: 25958710

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl at 1 mcg/kg/dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous ketamine at 1 mg/kg/dose
Number of subjects: 55
Study: 23239489

Group type: EXPERIMENTAL
Intervention: Full-length, wedged insole
Number of subjects: 14
Study: 21969011

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (increased from <5 to >5 MET h/wk or >30 MET h/wk)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Persistently active adolescents
Number of subjects: 553

Group type: COMPARATOR
Intervention: Sedentary adolescents
Number of subjects: 553
Study: 19635277

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg subcutaneously once daily for 12 weeks
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care (tinzaparin for >or=5 days plus oral warfarin for >or=12 weeks)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 480
Study: 16631323

Group type: EXPERIMENTAL
Intervention: ondansetron 4.0 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ondansetron 1.0 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 14983506

Group type: EXPERIMENTAL
Intervention: Behavioral risk factor reduction interventions in older adults
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Age-related vulnerability factors
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Comorbid conditions and social support
Number of subjects: 1247
Study: 11529585

Group type: EXPERIMENTAL
Intervention: Improved glycaemic control (IC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual glycaemic control (UC)
Number of subjects: 43
Study: 9778323

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (aspirin and ticlopidine)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Conventional anticoagulation (heparin or oral anticoagulant)
Number of subjects: 485
Study: 7513534

Group type: EXPERIMENTAL
Intervention: Low dose aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 3351175

Group type: EXPERIMENTAL
Intervention: Telephone support system (regular calls by a public health nurse, available to call nurse every weekday during normal working hours)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 182
Study: 31360880

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 48835
Study: 27159397

Group type: EXPERIMENTAL
Intervention: 15 mcg vaccine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 30 mcg vaccine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Both 15 mcg and 30 mcg vaccines
Number of subjects: 240
Study: 24717011

Group type: EXPERIMENTAL
Intervention: Intervention group receiving counselling sessions based on social cognitive theory and motivational interviewing starting at 8-9 months of age and ending at age 4
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Control group receiving regular services without the intervention
Number of subjects: 1369
Study: 23178540

Group type: EXPERIMENTAL
Intervention: 3-minute duration of wheelchair tilt-in-space and recline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1-minute duration of wheelchair tilt-in-space and recline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0-minute duration of wheelchair tilt-in-space and recline
Number of subjects: 9
Study: 21551462

Group type: EXPERIMENTAL
Intervention: Dabigatran 50 mg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1861
Study: 18481718

Group type: EXPERIMENTAL
Intervention: Acupuncture with pushing manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 80
Study: 16252079

Group type: EXPERIMENTAL
Intervention: Stent application
Number of subjects: 51

Group type: COMPARATOR
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 51
Study: 12674333

Group type: EXPERIMENTAL
Intervention: MTHFR TT genotype
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 1748
Study: 11104182

Group type: EXPERIMENTAL
Intervention: Cognitive preparation prior to video feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cognitive preparation (Control)
Number of subjects: 0
Study: 8931348

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (467 healthy controls)
Number of subjects: 17
Study: 1364968

Group type: EXPERIMENTAL
Intervention: Olimunostim (7 consecutive daily doses, perorally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 7372036

Group type: EXPERIMENTAL
Intervention: Treatment groups (individual-oriented intervention for high-risk subjects and mass health education for the remaining 70%)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Treatment groups (high-risk subgroups)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Treatment groups (random population)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Treatment groups (whole treatment populations)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Treatment groups
Number of subjects: 6000
Study: 30864474

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 289
Study: 27826781

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic surgery
Number of subjects: 221

Group type: COMPARATOR
Intervention: 2D laparoscopic surgery
Number of subjects: 221